Global Naloxone Market growing at a CAGR of 11.1% from 2023 to 2031
Category : Healthcare | Published Date : Oct 2023 | Type : Press Release | Author : Utsavi Upmanyue
Key Market Overview
Consegic Business Intelligence analyzes that the naloxone market is predicted to grow at a compound annual growth rate of 11.1% from 2023 to 2031 and is expected to reach USD 2,178.75 million in 2031 and 940.54 million in 2023 which was valued at USD 850.07 million in 2022.
The report highlights the increasing cases of opioids overdose across the globe, which is augmenting the global market growth. Consegic Business Intelligence study also provides insights into the market's competitive landscape, market segmentation, regional outlook, and emerging technologies in the naloxone market.
Global Naloxone Market By Overview
The naloxone market is bifurcated into the strength, route of administration and distribution channel. Based on the strength, the market is segmented into 2.0 mg/0.1 ml and 4.0 mg/ml, 1 mg/ml, 0.4 mg/ml, and Others. In 2022, the 2.0 mg/0.1 ml and 4.0 mg/ml segment dominate the overall naloxone market. Based on route of administration, the market is segmented into injectables, nasal, and oral. The injectables segment is further bifurcated into intramuscular or subcutaneous and intravenous. In 2022, the injectables segment dominates the overall naloxone market. Based on the distribution channel, the market is segmented into hospital pharmacies, retail stores, online pharmacies, and others. In 2022, the hospital pharmacies segment dominates the overall naloxone market.
Get Free SampleMarket Dynamics
Driver:
- Increasing cases of opioids overdose
- Growing access of naloxone along with rising government initiatives for the distribution of naloxone
Restraints:
- High cost of naloxone along with lower accessibility in emerging economies
Market Segmentation:
| Report Attributes | Report Details |
| By Strength | 2.0 mg/0.1 ml and 4.0 mg/ml, 1 mg/ml, 0.4 mg/ml, and Others |
| By Route of Administration | Injectables (Intramuscular or Subcutaneous and Intravenous), Nasal, and Oral |
| By Distribution Channel | Hospital Pharmacies, Retail Stores, Online Pharmacies, and Others |
| By Region | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Competitive Landscape :
The market is dominated by certain major companies such as Amphastar Pharmaceuticals, Inc., Emergent BioSolutions Inc., Hikama Pharmaceuticals PLC, and Indivior Plc., which have a strong market position in the current market circumstances. These companies are continuously leveraging new technologies to develop innovative solutions. Furthermore, the naloxone market is expected to witness substantial growth in the coming years due to growing investments in anti-opioid medication development in key regions such as North America, Asia Pacific, and others.
The market is characterized by intense competition, with companies focusing on expanding their product offerings and increasing their market share through mergers, acquisitions, and partnerships.
- Amphastar Pharmaceuticals, Inc.
- Emergent BioSolutions Inc.
- Hikama Pharmaceuticals PLC
- Indivior Plc.
- Kaleo, Inc.
- Kern Pharma, S.L.
- Mundipharma International Limited
- Novartis AG (Sandoz US)
- Pfizer, Inc.
- Viatris Inc.
- Padagis LLC
Our Clients
